| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveal Neoplasms | 23 | 2025 | 61 | 8.050 |
Why?
|
| Melanoma | 24 | 2025 | 975 | 5.170 |
Why?
|
| Retinal Neoplasms | 20 | 2023 | 103 | 4.390 |
Why?
|
| Retinoblastoma | 19 | 2023 | 117 | 4.020 |
Why?
|
| Brachytherapy | 11 | 2024 | 92 | 2.330 |
Why?
|
| Biopsy, Fine-Needle | 11 | 2020 | 123 | 2.200 |
Why?
|
| Gene Expression Profiling | 10 | 2024 | 1910 | 1.780 |
Why?
|
| Macular Edema | 5 | 2024 | 99 | 1.730 |
Why?
|
| Choroid Neoplasms | 4 | 2025 | 26 | 1.620 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2024 | 221 | 1.520 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 407 | 1.490 |
Why?
|
| Iodine Radioisotopes | 5 | 2024 | 78 | 1.400 |
Why?
|
| Intravitreal Injections | 7 | 2024 | 156 | 1.310 |
Why?
|
| Retinal Diseases | 4 | 2024 | 181 | 1.230 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 1386 | 1.220 |
Why?
|
| Ranibizumab | 4 | 2024 | 76 | 1.220 |
Why?
|
| Vitrectomy | 5 | 2024 | 112 | 1.200 |
Why?
|
| Endophthalmitis | 3 | 2021 | 78 | 1.190 |
Why?
|
| Retinal Perforations | 3 | 2024 | 27 | 1.150 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1720 | 1.110 |
Why?
|
| Sclera | 2 | 2018 | 58 | 1.090 |
Why?
|
| Nevus, Pigmented | 2 | 2025 | 34 | 1.030 |
Why?
|
| Retina | 4 | 2024 | 503 | 0.970 |
Why?
|
| Glaucoma, Neovascular | 1 | 2023 | 2 | 0.880 |
Why?
|
| Visual Acuity | 10 | 2024 | 869 | 0.860 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2024 | 39 | 0.850 |
Why?
|
| Vitreous Body | 6 | 2023 | 107 | 0.830 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2024 | 449 | 0.830 |
Why?
|
| Eye Injuries | 1 | 2023 | 52 | 0.820 |
Why?
|
| Radiation Injuries | 2 | 2024 | 165 | 0.790 |
Why?
|
| Optic Nerve Diseases | 1 | 2023 | 96 | 0.770 |
Why?
|
| Aged, 80 and over | 18 | 2025 | 7212 | 0.760 |
Why?
|
| Neutropenia | 1 | 2023 | 201 | 0.760 |
Why?
|
| Retrospective Studies | 32 | 2025 | 17488 | 0.730 |
Why?
|
| Masks | 1 | 2021 | 40 | 0.730 |
Why?
|
| Ultrasonography | 9 | 2019 | 1002 | 0.720 |
Why?
|
| Tomography, Optical Coherence | 7 | 2024 | 586 | 0.710 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 377 | 0.680 |
Why?
|
| Neoplasm Seeding | 2 | 2017 | 13 | 0.680 |
Why?
|
| Radiotherapy | 3 | 2020 | 148 | 0.660 |
Why?
|
| Aged | 24 | 2025 | 21746 | 0.630 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 144 | 0.610 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 962 | 0.610 |
Why?
|
| Infusions, Intra-Arterial | 4 | 2023 | 27 | 0.610 |
Why?
|
| Middle Aged | 26 | 2025 | 29409 | 0.600 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2018 | 51 | 0.570 |
Why?
|
| Male | 43 | 2025 | 65904 | 0.560 |
Why?
|
| Melphalan | 4 | 2023 | 45 | 0.550 |
Why?
|
| Follow-Up Studies | 11 | 2025 | 5511 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 2122 | 0.530 |
Why?
|
| Humans | 66 | 2025 | 133943 | 0.520 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 129 | 0.510 |
Why?
|
| Laser Therapy | 4 | 2008 | 252 | 0.510 |
Why?
|
| Eye Enucleation | 7 | 2019 | 54 | 0.500 |
Why?
|
| Female | 41 | 2025 | 71684 | 0.490 |
Why?
|
| Eye Neoplasms | 3 | 2023 | 53 | 0.490 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 1850 | 0.480 |
Why?
|
| Neoplasms, Vascular Tissue | 2 | 2012 | 4 | 0.480 |
Why?
|
| Topotecan | 3 | 2023 | 50 | 0.470 |
Why?
|
| Adult | 20 | 2025 | 31950 | 0.430 |
Why?
|
| Body Weight | 1 | 2018 | 1034 | 0.430 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2024 | 65 | 0.430 |
Why?
|
| Epiretinal Membrane | 3 | 2024 | 15 | 0.430 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 1788 | 0.430 |
Why?
|
| Conjunctival Neoplasms | 1 | 2013 | 22 | 0.420 |
Why?
|
| Eyelid Neoplasms | 1 | 2013 | 44 | 0.410 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 66 | 0.410 |
Why?
|
| Fluorescein Angiography | 5 | 2023 | 155 | 0.400 |
Why?
|
| Carboplatin | 4 | 2023 | 87 | 0.380 |
Why?
|
| Iris Diseases | 1 | 2011 | 15 | 0.380 |
Why?
|
| Neurofibromatosis 2 | 2 | 2010 | 10 | 0.370 |
Why?
|
| Laser Coagulation | 5 | 2021 | 132 | 0.370 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2024 | 510 | 0.350 |
Why?
|
| Melanosis | 2 | 2021 | 10 | 0.350 |
Why?
|
| Treatment Outcome | 11 | 2024 | 13013 | 0.350 |
Why?
|
| Infant | 16 | 2023 | 13163 | 0.340 |
Why?
|
| Abscess | 1 | 2011 | 141 | 0.340 |
Why?
|
| Candidiasis | 1 | 2011 | 138 | 0.340 |
Why?
|
| Ophthalmic Artery | 3 | 2023 | 23 | 0.320 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 1315 | 0.320 |
Why?
|
| Eye Evisceration | 1 | 2009 | 6 | 0.310 |
Why?
|
| Eye Infections, Bacterial | 2 | 2021 | 92 | 0.300 |
Why?
|
| Blindness | 1 | 2009 | 83 | 0.290 |
Why?
|
| Retinal Vessels | 1 | 2008 | 78 | 0.280 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 718 | 0.270 |
Why?
|
| Hyperthermia, Induced | 2 | 2004 | 59 | 0.270 |
Why?
|
| Retinal Detachment | 1 | 2008 | 87 | 0.270 |
Why?
|
| Basement Membrane | 2 | 2024 | 49 | 0.250 |
Why?
|
| Pain | 1 | 2009 | 478 | 0.240 |
Why?
|
| Young Adult | 9 | 2024 | 9890 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 1353 | 0.240 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2024 | 4 | 0.230 |
Why?
|
| Paraneoplastic Syndromes, Ocular | 1 | 2024 | 2 | 0.230 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2024 | 13 | 0.230 |
Why?
|
| Melanocytes | 1 | 2024 | 50 | 0.230 |
Why?
|
| RNA Splicing Factors | 1 | 2024 | 55 | 0.220 |
Why?
|
| Prostaglandins, Synthetic | 1 | 2024 | 3 | 0.220 |
Why?
|
| Genes, Neoplasm | 2 | 2017 | 90 | 0.220 |
Why?
|
| Vitreous Hemorrhage | 1 | 2023 | 10 | 0.220 |
Why?
|
| Prostaglandins | 1 | 2024 | 48 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1315 | 0.210 |
Why?
|
| Retinitis | 1 | 2023 | 18 | 0.210 |
Why?
|
| Eye Infections, Viral | 1 | 2023 | 29 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2024 | 6664 | 0.210 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2003 | 50 | 0.210 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 21 | 0.200 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2003 | 64 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 2 | 2019 | 164 | 0.200 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2019 | 90 | 0.190 |
Why?
|
| Lacrimal Apparatus | 1 | 2023 | 128 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2024 | 212 | 0.190 |
Why?
|
| Ophthalmology | 2 | 2020 | 217 | 0.190 |
Why?
|
| Phosphoproteins | 1 | 2024 | 456 | 0.190 |
Why?
|
| Retinitis Pigmentosa | 1 | 2023 | 95 | 0.190 |
Why?
|
| Choroid Diseases | 1 | 2021 | 23 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 388 | 0.180 |
Why?
|
| Ciliary Body | 2 | 2011 | 32 | 0.180 |
Why?
|
| Carcinoma | 1 | 2023 | 322 | 0.180 |
Why?
|
| Incidence | 3 | 2023 | 3402 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 216 | 0.170 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 317 | 0.170 |
Why?
|
| Uvea | 1 | 2019 | 3 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2019 | 8 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2019 | 24 | 0.160 |
Why?
|
| Dry Eye Syndromes | 1 | 2023 | 281 | 0.160 |
Why?
|
| Child, Preschool | 13 | 2020 | 14802 | 0.150 |
Why?
|
| Child | 9 | 2023 | 25742 | 0.150 |
Why?
|
| Fundus Oculi | 1 | 2018 | 69 | 0.150 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 119 | 0.140 |
Why?
|
| Choroid | 1 | 2017 | 43 | 0.140 |
Why?
|
| Femoral Artery | 1 | 2018 | 191 | 0.140 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 368 | 0.140 |
Why?
|
| Vincristine | 3 | 2010 | 195 | 0.130 |
Why?
|
| Mutation | 4 | 2024 | 6297 | 0.130 |
Why?
|
| ROC Curve | 1 | 2018 | 616 | 0.130 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 136 | 0.120 |
Why?
|
| Transcriptome | 2 | 2024 | 1127 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 777 | 0.120 |
Why?
|
| Biomarkers | 2 | 2024 | 3426 | 0.120 |
Why?
|
| Prognosis | 3 | 2024 | 5081 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 128 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2008 | 202 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 11101 | 0.110 |
Why?
|
| Triamcinolone Acetonide | 2 | 2016 | 37 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 3 | 2011 | 263 | 0.110 |
Why?
|
| Lasers, Semiconductor | 2 | 2010 | 9 | 0.100 |
Why?
|
| Time Factors | 3 | 2024 | 6590 | 0.100 |
Why?
|
| Biopsy | 2 | 2013 | 1304 | 0.100 |
Why?
|
| Monitoring, Intraoperative | 2 | 2010 | 135 | 0.100 |
Why?
|
| Retinoblastoma Protein | 2 | 2010 | 86 | 0.090 |
Why?
|
| United States | 3 | 2021 | 11687 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 238 | 0.090 |
Why?
|
| Iris Neoplasms | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cryotherapy | 2 | 2017 | 22 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2013 | 3851 | 0.090 |
Why?
|
| Candida albicans | 1 | 2011 | 90 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2016 | 3227 | 0.090 |
Why?
|
| Retinal Artery | 1 | 2010 | 17 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 4777 | 0.090 |
Why?
|
| Etoposide | 2 | 2010 | 120 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 104 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2011 | 372 | 0.080 |
Why?
|
| Tuberculosis, Ocular | 1 | 2009 | 4 | 0.080 |
Why?
|
| Retinal Vasculitis | 1 | 2009 | 9 | 0.080 |
Why?
|
| Macula Lutea | 1 | 2010 | 51 | 0.080 |
Why?
|
| Retinal Horizontal Cells | 1 | 2008 | 13 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2008 | 50 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2008 | 80 | 0.070 |
Why?
|
| Operating Rooms | 1 | 2008 | 75 | 0.070 |
Why?
|
| Pseudophakia | 1 | 2008 | 75 | 0.070 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 83 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2008 | 257 | 0.070 |
Why?
|
| Podophyllotoxin | 1 | 2007 | 7 | 0.070 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 15 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2008 | 176 | 0.070 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2008 | 105 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2010 | 8591 | 0.070 |
Why?
|
| Biometry | 1 | 2008 | 143 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1977 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2008 | 168 | 0.070 |
Why?
|
| Eye Diseases | 1 | 2008 | 138 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 110 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2010 | 1409 | 0.060 |
Why?
|
| Refraction, Ocular | 1 | 2008 | 316 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2008 | 406 | 0.060 |
Why?
|
| Cataract Extraction | 1 | 2008 | 221 | 0.060 |
Why?
|
| Phacoemulsification | 1 | 2008 | 243 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 175 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 704 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 344 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1629 | 0.060 |
Why?
|
| Endotamponade | 1 | 2024 | 11 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2519 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 607 | 0.060 |
Why?
|
| Pupil | 1 | 2004 | 74 | 0.050 |
Why?
|
| Lenses, Intraocular | 1 | 2008 | 403 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 168 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2004 | 244 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2003 | 41 | 0.050 |
Why?
|
| Prednisone | 1 | 2003 | 289 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2023 | 102 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2003 | 300 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2024 | 971 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2002 | 99 | 0.050 |
Why?
|
| Methotrexate | 2 | 2017 | 355 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2003 | 125 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 286 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 417 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 569 | 0.040 |
Why?
|
| Adolescent | 4 | 2010 | 20536 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 27 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2023 | 801 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2011 | 2526 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2000 | 72 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2010 | 104 | 0.040 |
Why?
|
| Injections | 2 | 2010 | 159 | 0.040 |
Why?
|
| Microscopy, Acoustic | 1 | 2017 | 17 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 2196 | 0.040 |
Why?
|
| Sclerosis | 2 | 2010 | 38 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 144 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2011 | 1242 | 0.030 |
Why?
|
| Macular Degeneration | 1 | 2016 | 128 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 2016 | 169 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 5182 | 0.030 |
Why?
|
| Bacteria | 1 | 2016 | 534 | 0.020 |
Why?
|
| Eye Color | 1 | 2011 | 7 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2011 | 107 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2010 | 18 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2010 | 13 | 0.020 |
Why?
|
| Polyethylene | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3740 | 0.020 |
Why?
|
| Internationality | 1 | 2011 | 138 | 0.020 |
Why?
|
| Orbital Implants | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2010 | 148 | 0.020 |
Why?
|
| Pyrazinamide | 1 | 2009 | 12 | 0.020 |
Why?
|
| Hypoxia | 1 | 2011 | 264 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 254 | 0.020 |
Why?
|
| Retinal Neovascularization | 1 | 2009 | 17 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 141 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 149 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2008 | 22 | 0.020 |
Why?
|
| Isoniazid | 1 | 2009 | 66 | 0.020 |
Why?
|
| Ophthalmoscopes | 1 | 2008 | 4 | 0.020 |
Why?
|
| Endoglin | 1 | 2008 | 30 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 317 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2009 | 123 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2008 | 50 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2008 | 52 | 0.020 |
Why?
|
| Telecommunications | 1 | 2008 | 22 | 0.020 |
Why?
|
| Rifampin | 1 | 2009 | 134 | 0.020 |
Why?
|
| Interferometry | 1 | 2008 | 28 | 0.020 |
Why?
|
| Microglia | 1 | 2010 | 138 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2008 | 108 | 0.020 |
Why?
|
| Mice | 3 | 2011 | 18909 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 273 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 1070 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 577 | 0.020 |
Why?
|
| Light | 1 | 2008 | 187 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 337 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 317 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 263 | 0.020 |
Why?
|
| Anesthesiology | 1 | 2008 | 103 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 621 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 452 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 351 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 494 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 2210 | 0.020 |
Why?
|
| Cataract | 1 | 2008 | 230 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1197 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2009 | 406 | 0.010 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2008 | 349 | 0.010 |
Why?
|
| Animals | 3 | 2011 | 36388 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2539 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 2242 | 0.010 |
Why?
|
| Tissue Embedding | 1 | 2003 | 4 | 0.010 |
Why?
|
| Ruthenium Radioisotopes | 1 | 2002 | 1 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 2002 | 47 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 3056 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 1411 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 4548 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 667 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2002 | 859 | 0.010 |
Why?
|